SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who wrote (1516)5/14/2003 8:19:07 AM
From: tom pope  Read Replies (1) of 3044
 
Here's Briefing's take:

06:06 ET MLNM Millennium Pharma receives rapid approval for Velcade (12.49)
Analysts are positively surprised after Millennium Pharma's surprise approval for Velcade for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy. The approval comes approx 1.5 quarters ahead of expectations and with a broader label than the majority of analyst community had expected possibly doubling the revenue potential. This news can be viewed as a considerable negative for Celgene (CELG) whose lead drug Thalomid (not approved for MM) will face strong competition from Velcade.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News